

AHL/AO/2026/1093

Date: 09.02.2026

To  
The BSE Limited  
Listing Department  
25th Floor, Phiroze Jeejeebhoy Tower  
Dalal Street  
Mumbai – 400 001

**Sub:** Outcome of Board Meeting held on 09 February 2026 and Submission of Unaudited Financial Results for the Quarter Ended 31st December 2025 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**Ref:** Scrip Code: 543943

Dear Sir/Ma'am,  
Pursuant to the provisions of Regulation 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we wish to inform you that the Board of Directors of **Asarfi Hospital Limited** ("the Company"), at its meeting held today i.e. **09 February, 2026**, has considered and approved the **Unaudited Standalone and Consolidated Financial Results** of the Company for the quarter ended **31st December, 2025**.

A copy of the aforesaid Unaudited Standalone and Consolidated Financial Results along with the **Limited Review Report** issued by the Statutory Auditors is enclosed herewith.

The Board Meeting commenced at **03:00 P.M.** and concluded at **06:00 P.M.**

You are requested to kindly take the above information on record.

Thanking you,  
Yours faithfully,  
For **Asarfi Hospital Limited**

  
**Sudipa Singh**

Company Secretary & Compliance Officer  
Membership No.: **ACS 56989**



---

## Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673  
Branch Office: Khatal Road, Dhaiya, ISM, Dhanbad 826004 || [www.asarfihospital.com](http://www.asarfihospital.com)  
Phone: 7808368888, 9234302735 || Email: [info@asarfihospital.com](mailto:info@asarfihospital.com)

AHL/AO/2026/1094

Date: 09.02.2026

To,  
The BSE Limited  
Listing Department  
25th Floor, Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai – 400 001

**Sub:** Declaration regarding unaudited Reports with unmodified opinion on the Financial Statements (Standalone and Consolidated) of the Company for the Financial Results of Quarter ended December 31, 2025

**Ref:** Scrip Code: 543943

Dear Sir/Madam,


Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that **M/s R. K. Thakkar & Co., Chartered Accountants**, Statutory Auditors of the Company, have issued **Audit Reports with unmodified opinion** on the **Standalone and Consolidated Financial Statements** of the Company for the **financial Quarter ended December 31, 2025**.

This is for your kind information and records.

Thanking you,

Yours faithfully,

For **Asarfi Hospital Limited**

  
**Sudipa Singh**



Company Secretary & Compliance Officer

Membership No.: **ACS 56989**

---

## Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673  
Branch Office: Khatal Road, Dhaiya, ISM, Dhanbad 826004 || [www.asarfihospital.com](http://www.asarfihospital.com)  
Phone: 7808368888, 9234302735 || Email: [info@asarfihospital.com](mailto:info@asarfihospital.com)

# **M/S R. K. THAKKAR & CO.**

## **Chartered Accountants**

---

Below 'Central Bank of India', Bank More, Dhanbad, 826001  
Mobile: 6203797936; email: rkthakkarco@gmail.com

---

**Independent Auditor's Limited Review Report on the Quarterly and Nine Months Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to,  
The Board of Directors,  
**Asarfi Hospital Limited**  
Baramuri, Bishunpur Polytechnic,  
Dhanbad- 828130 Jharkhand

Dear Sir,

**Re:** Limited Review Report of the Unaudited Standalone Financial Results for the Nine Months and Quarter ended 31<sup>st</sup> December, 2025.

We have reviewed the accompanying statement of unaudited standalone financial results of **ASARFI HOSPITAL LIMITED**, for the Nine Months and Quarter ended 31<sup>st</sup> December, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, ('the Regulation') as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.



We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of SEBI ( Listing Obligations and Disclosure Requirement) , read with the Circular, including the matter in which it is to be disclosed, or that it contains any material misstatement.

**For R K Thakkar & Co**  
**Chartered Accountants**  
**FRN: 002690C**

**Place: Dhanbad**  
**Date: 09.02.2026**  
**UDIN: 26415931WBAKIO5355**

  
  
**Himanshu Kumar Dokania**  
**(Partner)**  
**Membership No. 415931**

**Asarfi Hospital Limited**

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

**Standalone Unaudited Balance Sheet as at 31st December 2025**

(₹ in 'Lakhs)

Particulars	As at	
	31-Dec-25	31-Mar-25
	Unaudited	Audited
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholders' funds</b>		
(a) Share Capital	1,967.73	1,967.73
(b) Reserves and Surplus	7,474.34	6,176.00
<b>Total</b>	<b>9,442.07</b>	<b>8,143.73</b>
<b>(2) Non-current liabilities</b>		
(a) Long-term Borrowings	3,130.52	3,382.93
(b) Deferred Tax Liabilities (net)	360.78	337.07
(c) Other Long-term Liabilities	104.07	346.34
(d) Long-term Provisions	123.33	120.09
<b>Total</b>	<b>3,718.70</b>	<b>4,186.42</b>
<b>(3) Current liabilities</b>		
(a) Short-term Borrowings	2,312.19	1,472.80
(b) Trade Payables		
- Due to Micro and Small Enterprises	14.29	17.65
- Due to Others	1,562.27	1,285.68
(c) Other Current Liabilities	876.01	765.29
(d) Short-term Provisions	629.58	559.00
<b>Total</b>	<b>5,394.35</b>	<b>4,100.42</b>
<b>Total Equity and Liabilities</b>	<b>18,555.12</b>	<b>16,430.57</b>
<b>II. ASSETS</b>		
<b>(1) Non-current assets</b>		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	9,657.91	10,148.36
(ii) Capital Work-in-progress	515.43	193.91
(b) Non-current Investments	1.00	1.00
(c) Long term Loans and Advances	305.55	86.23
(d) Other Non-current Assets	519.29	163.88
<b>Total</b>	<b>10,999.18</b>	<b>10,593.37</b>
<b>(2) Current assets</b>		
(a) Inventories	292.62	227.67
(b) Trade Receivables	5,459.91	3,979.73
(c) Cash and cash equivalents	1,701.79	131.56
(d) Short-term Loans and Advances	86.64	87.44
(e) Other Current Assets	14.98	1,410.81
<b>Total</b>	<b>7,555.94</b>	<b>5,837.20</b>
<b>Total Assets</b>	<b>18,555.12</b>	<b>16,430.57</b>



For and on behalf of the Board of

Asarfi Hospital Limited



*Udai Pratap Singh*  
Udai Pratap Singh

Managing Director  
08453794

*Madhuri Singh*  
Madhuri Singh

Director  
6562038

*Harendra Singh*  
Harendra Singh

CFO  
BANPS9243R

*CS Sudipa Singh*  
CS Sudipa Singh

Company Secretary  
ACS No.56989

Place: Dhanbad  
Date: 09.02.2026

(₹ in 'Lakhs)

Particulars	Quarter Ended			Nine Months Ended	Nine Months Ended	Year Ended
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from Operations	4,605.87	4,484.67	3,289.01	12,656.94	8,667.37	12,056.57
Other Income	149.82	79.75	89.47	371.20	270.02	756.90
<b>Total Income</b>	<b>4,755.69</b>	<b>4,564.42</b>	<b>3,378.48</b>	<b>13,028.14</b>	<b>8,937.39</b>	<b>12,813.47</b>
<b>Expenses</b>						
Cost of Material Consumed	655.85	740.39	488.70	1,986.80	1,435.87	1,939.98
Purchases of Stock in Trade	322.99	330.79	257.84	958.43	661.38	909.31
Change in Inventories of work in progress and finished goods	-2.17	-11.83	-28.43	-51.83	-60.83	-63.37
Employee Benefit Expenses	747.74	609.82	452.33	1,935.71	1,271.01	1,861.02
Finance Costs	125.45	106.53	117.50	353.86	273.33	408.09
Depreciation and Amortization Expenses	285.67	288.30	303.63	869.92	938.72	1,261.74
Other Expenses	1,869.62	1,924.56	1,421.02	5,221.71	3,499.97	5,025.24
<b>Total expenses</b>	<b>4,005.15</b>	<b>3,988.56</b>	<b>3,012.59</b>	<b>11,274.61</b>	<b>8,019.45</b>	<b>11,342.01</b>
<b>Profit/(Loss) before Exceptional and Extraordinary Item and Tax</b>	<b>750.54</b>	<b>575.86</b>	<b>365.89</b>	<b>1,753.53</b>	<b>917.94</b>	<b>1,471.46</b>
Exceptional Item						
<b>Profit/(Loss) before Extraordinary Item and Tax</b>	<b>750.54</b>	<b>575.86</b>	<b>365.89</b>	<b>1,753.53</b>	<b>917.94</b>	<b>1,471.46</b>
Extraordinary Item						-
<b>Profit/(Loss) before Tax</b>	<b>750.54</b>	<b>575.86</b>	<b>365.89</b>	<b>1,753.53</b>	<b>917.94</b>	<b>1,471.46</b>
Tax Expenses						
- Current Tax	152.71	138.35	163.48	398.56	163.48	307.56
- Deferred Tax	16.62	7.09	-69.52	23.71	38.90	65.46
- Prior Period Taxes	32.92	-	-	32.92	0.46	0.46
<b>Profit/(Loss) after Tax</b>	<b>548.29</b>	<b>430.42</b>	<b>271.93</b>	<b>1,298.34</b>	<b>715.10</b>	<b>1,097.97</b>
<b>Profit/(Loss) for the period (before Minority interest adjustment)</b>	<b>548.29</b>	<b>430.42</b>	<b>271.93</b>	<b>1,298.34</b>	<b>715.10</b>	<b>1,097.97</b>
Less: Minority interest in (Profit)/losses	-	-	-	-	-	-
<b>Profit/(Loss) for the period (after Minority interest adjustment)</b>	<b>548.29</b>	<b>430.42</b>	<b>271.93</b>	<b>1,298.34</b>	<b>715.10</b>	<b>1,097.97</b>
Earnings Per Share (Face Value per Share Rs.10 each)						
- Basic (In Rs)	2.79	2.19	1.38	6.60	3.63	5.58
- Diluted (In Rs)	2.79	2.19	1.38	6.60	3.63	5.58

1 The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on 9th February, 2026

2 The Statutory Auditor of the company carried out the limited Review of above result as per Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 As per Accounting Standard - 17 on "Segment Reporting" (AS 17), the company has only one reportable segment viz Hospital.

4 As per MCA notification dated 16th February 2015 companies whose shares are listed in SME exchange as referred to Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018 are exempted from compulsory requirement of adoption of IND AS.

5 Earning per Share are calculated on weighted average of the share capital outstanding during the year/ half year/ period EPS is not annualised.

6 Previous year's/ period's have been regrouped/ rearranged wherever necessary.



Place: Dhanbad  
Date: 09.02.2026

*Udai Pratap Singh*  
Udai Pratap Singh  
Managing Director  
0845379413

*Harendra Singh*  
Harendra Singh  
CFO  
BANPS9243R

*Madhuri Singh*  
Madhuri Singh  
Director  
6562038

*Sudipa Singh*  
For and on behalf of the Board  
Asarfi Hospital Limited  
Dhanbad  
CS Sudipa Singh  
Company Secretary  
ACS No.56989

**Asarfi Hospital Limited**

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

**Unaudited Cash Flow Statement for the period ended 31st December 2025**

(₹ in 'Lakhs)

Particulars	Period Ended	Year ended
	31-Dec-25	31-Mar-25
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit after tax	1,298.34	1,097.97
Profit/(loss) from Discontinuing Operation (after tax)	-	-
Depreciation and Amortisation Expense	869.92	1,261.74
Provision for tax	455.19	373.49
Loss/(Gain) on Sale / Discard of Assets (Net)	-2.34	-39.80
Non operating Income	-	-323.82
Non operating Expenses	4.02	30.99
Interest Income	-71.21	-125.68
Finance Costs	325.87	408.09
<b>Operating Profit before working capital changes</b>	<b>2,879.80</b>	<b>2,682.98</b>
<b>Adjustment for:</b>		
Inventories	-64.95	-47.68
Trade Receivables	-1,484.20	-1,554.02
Loans and Advances	-33.21	256.55
Other Current Assets	-0.90	-8.27
Other Non current Assets	15.84	-
Trade Payables	277.35	-1,193.69
Other Current Liabilities	96.57	-106.38
Long term Liabilities	-242.27	-340.74
Short-term Provisions	72.08	212.79
Long-term Provisions	3.25	22.22
Cash (Used in)/Generated from Operations	1,519.36	-76.23
Tax paid(Net)	432.98	308.03
<b>Net Cash (Used in)/Generated from Operating Activities</b>	<b>1,086.38</b>	<b>-384.26</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Property, Plant and Equipment & CWIP	-808.81	-968.85
Sale of Property, Plant and Equipment	-	129.15
Decrease /Increase in Capital WIP	-	-193.91
Loans and Advances given	-65.14	-72.64
Proceeds from Loans and Advances	-	-
Investment/Reclassification in/to Term Deposits	316.62	-
Maturity of Term Deposits	-	183.32
Movement in other non current assets	-	7.09
Interest received	71.21	125.68
Dividend received	-	-
<b>Net Cash (Used in)/Generated from Investing Activities</b>	<b>-486.11</b>	<b>-790.16</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long Term Borrowings	267.04	2,203.80
Repayment of Long Term Borrowings	-519.45	-467.73
Proceeds from Short Term Borrowings	839.39	13.27
Repayment of Short Term Borrowings	-	-84.83
Interest Paid	-325.87	-407.63
Net Cash (Used in)/Generated from Financing Activities	261.10	1,256.88
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>	<b>861.37</b>	<b>82.46</b>
Opening Balance of Cash and Cash Equivalents	131.56	49.10
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
<b>Closing Balance of Cash and Cash Equivalents</b>	<b>992.93</b>	<b>131.56</b>



*Signature*



Components of cash and cash equivalents	31-Dec-25	31-March-2025
Cash on hand	45.74	105.64
Cheques, drafts on hand	-	-
Balances with banks in current accounts	569.47	25.91
Bank Deposit having maturity of less than 3 months	377.72	-
Others	-	-
<b>Cash and cash equivalents as per Cash Flow Statement</b>	<b>992.93</b>	<b>131.56</b>
<b>Other Bank Balance</b>		
Bank Deposit having maturity of greater than 3 months and less than 12 months	708.86	-
Bank Deposit having maturity of greater than 12 months	-	-
Less: Deposits reclassified to other non current assets	-	-
<b>Cash and bank balance as per Balance Sheet</b>	<b>1,701.79</b>	<b>131.56</b>

**Note:**

1. The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

**2. Reclassification of Fixed Deposit Balances**

Fixed deposits with original maturity of more than three months but less than twelve months were previously presented under Other Current Assets in the audited financial statements for the year ended 31 March 2025. For the purpose of the Quarterly financial results ended 31st December 2025, these have been reclassified under "Other Bank Balances" (forming part of Cash and Cash Equivalents) in accordance with Schedule III and AS 3. The reclassification has no impact on the total assets, liabilities or profit of the Company. Previous period figures have not been restated.



Place: Dhanbad  
Date: 09.02.2026

*Udai Pratap Singh*

**Udai Pratap Singh**  
Managing Director  
08453794

*माधुरी सिंह*

**Madhuri Singh**  
Director  
6562038

*Harendra Singh*

**Harendra Singh**  
CFO  
BANPS9243R

*Sudipa Singh*

**CS Sudipa Singh**  
Company Secretary  
ACS No.56989

For and on behalf of the Board of  
Asahi Hospital Limited





# **M/S R. K. THAKKAR & CO.**

## **Chartered Accountants**

---

Below 'Central Bank of India', Bank More, Dhanbad, 826001  
Mobile: 6203797936; email: rkthakkarco@gmail.com

---

**Independent Auditor's Limited Review Report on the Quarterly and Nine Months Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to,  
The Board of Directors,  
**Asarfi Hospital Limited**  
Baramuri, Bishunpur Polytechnic,  
Dhanbad- 828130 Jharkhand

Dear Sir,

**Re:** Limited Review Report of the Unaudited Consolidated Financial Results for the Nine Months and Quarter ended 31<sup>st</sup> December, 2025.

We have reviewed the accompanying statement of unaudited consolidated financial results of **ASARFI HOSPITAL LIMITED**, which include its subsidiary namely *Asarfi Educational Foundation*, for the Nine Months and Quarter ended 31<sup>st</sup> December, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, ('the Regulation') as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.



We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of SEBI ( Listing Obligations and Disclosure Requirement), read with the Circular, including the matter in which it is to be disclosed, or that it contains any material misstatement.

**For R K Thakkar & Co**  
**Chartered Accountants**  
**FRN: 002690C**

**Place: Dhanbad**  
**Date: 09.02.2026**  
**UDIN: 26415931XMJREZ7842**

  
  
**Himanshu Kumar Dokania**  
**(Partner)**  
**Membership No. 415931**

**Asarfi Hospital Limited**

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

**Unaudited Consolidated Balance Sheet as at 31st December 2025**

(₹ in 'Lakhs)

Particulars	As at	
	31-Dec-25	31-Mar-25
	Unaudited	Audited
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholders' funds</b>		
(a) Share Capital	1,967.73	1,967.73
(b) Reserves and Surplus	7,404.85	6,130.59
<b>Total</b>	<b>9,372.58</b>	<b>8,098.32</b>
<b>(2) Non-current liabilities</b>		
(a) Long-term Borrowings	3,130.52	3,382.93
(b) Deferred Tax Liabilities (net)	360.78	337.07
(c) Other Long-term Liabilities	104.07	346.34
(d) Long-term Provisions	123.33	120.09
<b>Total</b>	<b>3,718.70</b>	<b>4,186.42</b>
<b>(3) Current liabilities</b>		
(a) Short-term Borrowings	2,312.19	1,472.80
(b) Trade Payables		
- Due to Micro and Small Enterprises	14.29	17.65
- Due to Others	1,562.55	1,285.92
(c) Other Current Liabilities	890.51	767.19
(d) Short-term Provisions	629.80	560.36
<b>Total</b>	<b>5,409.34</b>	<b>4,103.92</b>
<b>Total Equity and Liabilities</b>	<b>18,500.63</b>	<b>16,388.67</b>
<b>II. ASSETS</b>		
<b>(1) Non-current assets</b>		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	9,667.77	10,164.44
(ii) Capital Work-in-progress	515.43	193.91
(b) Non-current Investments	-	-
(c) Long term Loans and Advances	154.17	-
(d) Other Non-current Assets	591.04	181.88
<b>Total</b>	<b>10,928.41</b>	<b>10,540.23</b>
<b>(2) Current assets</b>		
(a) Inventories	292.62	227.67
(b) Trade Receivables	5,463.22	3,979.73
(c) Cash and cash equivalents	1,714.70	142.63
(d) Short-term Loans and Advances	86.69	87.61
(e) Other Current Assets	14.98	1,410.81
<b>Total</b>	<b>7,572.22</b>	<b>5,848.44</b>
<b>Total Assets</b>	<b>18,500.63</b>	<b>16,388.67</b>



Place: Dhanbad  
Date: 09.02.2026

  
Udai Pratap Singh  
Managing Director  
08453794

  
Madhuri Singh  
Director  
6562038

  
Harendra Singh  
CFO  
BANPS9243R

For and on behalf of the Board of  
Asarfi Hospital Limited



  
CS Sudipa Singh  
Company Secretary  
ACS No.56989

(₹ in 'Lakhs)

Particulars	Quarter Ended			Nine Months Ended	Nine Months Ended	Year ended
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from Operations	4,609.52	4,489.06	3,289.01	12,666.69	8,667.37	12,056.57
Other Income	147.72	75.92	89.47	365.26	270.02	751.99
<b>Total Income</b>	<b>4,757.23</b>	<b>4,564.98</b>	<b>3,378.48</b>	<b>13,031.96</b>	<b>8,937.39</b>	<b>12,808.56</b>
<b>Expenses</b>						
Cost of Material Consumed	655.85	740.39	488.70	1,986.80	1,435.87	1,939.98
Purchases of Stock in Trade	322.99	330.79	257.84	958.43	661.38	909.31
Change in Inventories of work in progress and finished goods	(2.17)	(11.83)	(28.43)	(51.83)	(60.83)	(63.37)
Employee Benefit Expenses	749.19	612.31	452.75	1,941.83	1,271.44	1,863.23
Finance Costs	125.45	106.53	117.50	353.86	273.34	408.09
Depreciation and Amortization Expenses	288.17	291.28	304.90	878.58	942.57	1,267.60
Other Expenses	1,873.09	1,930.34	1,422.78	5,234.83	3,512.04	5,052.61
<b>Total expenses</b>	<b>4,012.56</b>	<b>3,999.81</b>	<b>3,016.04</b>	<b>11,302.50</b>	<b>8,035.81</b>	<b>11,377.45</b>
<b>Profit/(Loss) before Exceptional and Extraordinary Item and Tax</b>	<b>744.67</b>	<b>565.17</b>	<b>362.44</b>	<b>1,729.45</b>	<b>901.58</b>	<b>1,431.11</b>
Exceptional Item						
<b>Profit/(Loss) before Extraordinary Item and Tax</b>	<b>744.67</b>	<b>565.17</b>	<b>362.44</b>	<b>1,729.45</b>	<b>901.58</b>	<b>1,431.11</b>
Extraordinary Item						
<b>Profit/(Loss) before Tax</b>	<b>744.67</b>	<b>565.17</b>	<b>362.44</b>	<b>1,729.45</b>	<b>901.58</b>	<b>1,431.11</b>
Tax Expenses						
- Current Tax	152.71	138.35	163.48	398.56	163.48	307.56
- Deferred Tax	16.62	7.09	(69.52)	23.71	38.90	65.46
-Prior Period Taxes	32.92	-	-	32.92	0.46	0.46
<b>Profit/(Loss) after Tax</b>	<b>542.42</b>	<b>419.73</b>	<b>268.48</b>	<b>1,274.26</b>	<b>698.74</b>	<b>1,057.62</b>
<b>Profit/(Loss) for the period (before Minority interest adjustment)</b>	<b>542.42</b>	<b>419.73</b>	<b>268.48</b>	<b>1,274.26</b>	<b>698.74</b>	<b>1,057.62</b>
Less: Minority interest in (Profit)/losses						
<b>Profit/(Loss) for the period (after Minority interest adjustment)</b>	<b>542.42</b>	<b>419.73</b>	<b>268.48</b>	<b>1,274.26</b>	<b>698.74</b>	<b>1,057.62</b>
Earnings Per Share (Face Value per Share Rs.10 each)						
-Basic (In Rs)	2.76	2.13	1.36	6.48	3.55	5.37
-Diluted (In Rs)	2.76	2.13	1.36	6.48	3.55	5.37

1 The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on 9th February, 2026.

2 The Statutory Auditor of the company carried out the limited Review of above result as per Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 As per Accounting Standard - 17 on "Segment Reporting" (AS 17), the company has only one reportable segment viz Hospital.

4 As per MCA notification dated 16th February 2015 companies whose shares are listed in SME exchange as referred to Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018 are exempted from compulsory requirement of adoption of IND AS.

5 Earning per Share are calculated on weighted average of the share capital outstanding during the year/ half year/ period EPS is not annualised.

6 Previous year's/ period's have been regrouped/ rearranged wherever necessary.



Place: Dhanbad  
Date: 09.02.2026

*Udai Pratap Singh*

Udai Pratap Singh  
Managing Director  
084537943

*Harendra Singh*

Harendra Singh  
CFO  
BANPS9243R



*Madhuri Singh*  
Madhuri Singh  
Director  
6562038

*CS Sudipa Singh*  
CS Sudipa Singh  
Company Secretary  
ACS No.56989

**Asarfi Hospital Limited**

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

**Unaudited Consolidated Cash Flow Statement for the Period ended 31st December 2025**

(₹ in 'Lakhs)

Particulars	Period ended	Year Ended
	31-Dec-25	31-Mar-25
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit after tax	1,274.26	1,057.62
Profit/(loss) from Discontinuing Operation (after tax)	-	-
	-	-
Depreciation and Amortisation Expense	878.58	1,267.60
Provision for tax	455.19	373.49
Loss/(Gain) on Sale / Discard of Assets (Net)	(2.34)	(39.80)
Non operating Income	-	(323.82)
Non operating Expenses	4.02	30.99
Interest Income	(65.28)	(120.77)
Finance Costs	325.87	408.09
<b>Operating Profit before working capital changes</b>	<b>2,870.31</b>	<b>2,653.40</b>
<b>Adjustment for:</b>		
Inventories	(64.95)	(47.68)
Trade Receivables	(1,488.57)	(1,554.02)
Loans and Advances	(33.26)	256.42
Other Current Assets	(0.90)	(8.27)
Other Non current Assets	15.84	(18.00)
Trade Payables	277.40	(1,199.87)
Other Current Liabilities	110.22	(104.48)
Long term Liabilities	(242.27)	(340.74)
Short-term Provisions	70.94	214.05
Long-term Provisions	3.25	22.22
	-	-
Cash (Used in)/Generated from Operations	1,518.01	(126.95)
Tax paid(Net)	432.98	308.03
<b>Net Cash (Used in)/Generated from Operating Activities</b>	<b>1,085.03</b>	<b>(434.98)</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Property, Plant and Equipment & CWIP	(811.24)	(984.81)
Sale of Property, Plant and Equipment	-	129.15
Decrease /Increase in Capital WIP	-	(193.91)
Loans and Advances given	0.17	-
Investment/Reclassification in/to Term Deposits	316.62	-
Maturity of Term Deposits	-	183.32
Movement in other non current assets	(53.75)	7.09
Interest received	65.28	120.77
Dividend received	-	-
<b>Net Cash (Used in)/Generated from Investing Activities</b>	<b>(482.92)</b>	<b>(738.39)</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long Term Borrowings	267.04	2,203.80
Repayment of Long Term Borrowings	(519.45)	(467.73)
Proceeds from Short Term Borrowings	839.39	13.27
Repayment of Short Term Borrowings	-	(84.83)
Interest Paid	(325.87)	(407.63)
Net Cash (Used in)/Generated from Financing Activities	261.10	1,256.88
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>	<b>863.21</b>	<b>83.51</b>
Opening Balance of Cash and Cash Equivalents	142.63	59.12
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
<b>Closing Balance of Cash and Cash Equivalents</b>	<b>1,005.84</b>	<b>142.63</b>



Components of cash and cash equivalents	31 December 2025	31-March-2025
Cash on hand	46.61	105.78
Cheques, drafts on hand	-	-
Balances with banks in current accounts	581.51	36.84
Bank Deposit having maturity of less than 3 months	377.72	-
Others	-	-
<b>Cash and cash equivalents as per Cash Flow Statement</b>	<b>1,005.84</b>	<b>142.63</b>
<b>Other Bank Balance</b>		
Bank Deposit having maturity of greater than 3 months and less than 12 months	708.86	-
Bank Deposit having maturity of greater than 12 months	-	-
Less: Deposits reclassified to other non current assets	-	-
<b>Cash and bank balance as per Balance Sheet</b>	<b>1,714.70</b>	<b>142.63</b>

**Note:**

1. The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

**2. Reclassification of Fixed Deposit Balances**

Fixed deposits with original maturity of more than three months but less than twelve months were previously presented under Other Current Assets in the audited financial statements for the year ended 31 March 2025. For the purpose of the Quarterly financial results ended 31 December 2025, these have been reclassified under "Other Bank Balances" (forming part of Cash and Cash Equivalents) in accordance with Schedule III and AS 3. The reclassification has no impact on the total assets, liabilities or profit of the Company. Previous period figures have not been restated.



Place: Dhanbad  
Date: 09.02.2026

  
**Udai Pratap Singh**  
Managing Director  
08453794

  
**Madhuri Singh**  
Director  
6562038

  
**Harendra Singh**  
CFO  
BANPS9243R

For and on behalf of the Board of  
Asarfi Hospital Limited  
Dhanbad

  
**CS Sudipa Singh**  
Company Secretary  
ACS No.56989